NASDAQ:TTRX Turn Therapeutics Q2 2026 Earnings Results & Report $8.59 -0.76 (-8.14%) As of 04:00 PM Eastern This is a fair market value price provided by Massive. Learn more. Turn Therapeutics reported Q2 2026 earnings on August 12, 2026. The company reported EPS of -$0.20. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 12, 2026TimeAfter Market ClosesConference Call4:00 PM ET Turn Therapeutics EPS ResultsActual EPS-$0.20Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ATurn Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Turn Therapeutics Q2 2026 Earnings FAQ Did Turn Therapeutics beat earnings estimates for Q2 2026? Turn Therapeutics (NASDAQ:TTRX) reported earnings of -$0.20 per share for Q2 2026. The report was announced on Wednesday, August 12, 2026. Turn Therapeutics Earnings HeadlinesTurn Therapeutics to Present at Jefferies Global Healthcare Conference in LondonNovember 16 at 7:42 AM | marketscreener.comMTurn Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 9, 2026 | marketscreener.comMWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 16 at 1:00 AM | Base Camp Trading (Ad)Turn Therapeutics Inc. GAAP EPS of -$0.21November 9, 2026 | seekingalpha.comTurn Therapeutics (NASDAQ:TTRX) Stock Rating Lowered by Wall Street ZenNovember 8, 2026 | americanbankingnews.comTurn Therapeutics’ GX-03 Earns "Developmental Immunology Solution of the Year" in 2026 BioTech Breakthrough Awards ProgramNovember 5, 2026 | finance.yahoo.comSee More Turn Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Turn Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Turn Therapeutics and other key companies, straight to your email. Email Address About Turn TherapeuticsTurn Therapeutics (NASDAQ:TTRX) is a biotechnology company focused on developing topical products for skin health, wound care and infection management. Its work centers on formulations intended to deliver antimicrobial treatment directly to affected areas. The company has developed products for wound care and other topical applications, using its formulation technology to address needs in dermatology and related fields. Turn Therapeutics is based in the United States and has focused on developing and commercializing its products in the U.S. market.View Turn Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need? Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.